Tharimmune, Inc. THAR
Set alert
As of Apr 22, 12:59 PM ET
- YTD
- +16.83%
- 1 year
- +207.83%
- Open
- 3.34
- Prev close
- 3.54
- Mkt cap
- 3.11M
- Vol
- 358.85K
- Avg vol
- 1.26M
- EPS
- 61.01
- P/E
- 0.03
- Div yield
- 0.00%
More statistics
- Low
- 3.32
- High
- 3.58
- Forward P/E
- -17.42
- Beta
- 1.45
- Short ratio
- 0.02
- Inst. own
- 1.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 21, 2024
- 50-d avg
- 2.29
- 200-d avg
- 3.71
- 1y target
- 0.00
6M chart
Signals (26)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| RSI: Overbought | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| RSI: Overbought | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 9, 2025 | 10 months ago |
| SMA: Bearish | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 5, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 8, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| RSI: Overbought | Aug 20, 2025 | 1 year ago |
Key statistics
- Market cap
- 3.11M
- Enterprise value
- -1.70M
- Trailing P/E
- 0.03
- Forward P/E
- -17.42
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.89
- EPS (TTM)
- 61.01
- Beta
- 1.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.34M
- Total cash
- 4.77M
- Total debt
- 0
- Return on equity
- -454.53%
- Shares outstanding
- 1.49M
- Short % of float
- 4.42%
- 50-day average
- 2.29
- 200-day average
- 3.71
Analyst view
Consensus: none
Next earnings
Mar 21, 2024
Expected Mar 21, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -2.45 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -2.42 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -2.85 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.05 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -18.74 | -41.23 | -22.49 | -120.01% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Rodman & Renshaw | init | — | Buy |
About Tharimmune, Inc.
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tharimmune.com
News
- Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar
- Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
- Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
- Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
- Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Tharimmune Announces Expanded Role as Super Validator on Canton Network
- Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
Your note
Sign in to keep a note on THAR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPAJOSYULA SIREESH | Chief Operating Officer | Purchase | Nov 12, 2024 | 13,372 |
| MILBY RANDY | Chief Executive Officer | Purchase | Dec 18, 2024 | 17,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Curi RMB Capital, LLC | 1.22% | 23,620 | 49.37K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 627 | 1.31K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 2 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 9 | 18 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.29% | 5,582 | 11.67K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,350 | 2.82K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 29 | 60 | Sep 29, 2024 |